AIM-listed Neuropharm lines up GT as liquidators
Grant Thornton's Samantha Jane Keen and Ian Carr lined up for joint liquidators' role at Neuropharm
directors are proposing to put the AIM-listed company into a members’ voluntary
The company wants to pay off its liabilities and return any left-over funds
to its shareholders.
Thornton’s Samantha Jane Keen and Ian Carr would be appointed joint
liquidators under the proposal.
The company had failed to show through clinical trials that its treatment for
autistic disorder, NPL-2008, would improve patients’ health. Attempts to
continue its trials, or a sale of the business, fell through.